直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Two New Precedential PTAB Decisions Applying the Fintiv Factors

December 22, 2020

Authored and Edited by Amanda K. Murphy, Ph.D.; Kevin D. Rodkey

On Thursday, December 17, 2020, the Board designated portions of two decisions applying the Fintiv factors as precedential:  Sotera Wireless, Inc. v. Masimo Corp., IPR2020-01019, Paper 12 (Dec. 1, 2020) (precedential as to § II.A) and Snap, Inc. v. SRK Technology LLC, IPR2020-00820, Paper 15 (Oct. 21, 2020) (precedential as to § II.A). 

The Fintiv factors, set forth below, guide the Board’s analysis regarding whether to deny institution under 35 U.S.C. § 314(a) in view of a related litigation:

  1. whether the court granted a stay or evidence exists that one may be granted if a proceeding is instituted;
  2. proximity of the court’s trial date to the Board’s projected statutory deadline for a final written decision;
  3. investment in the parallel proceeding by the court and the parties;
  4. overlap between issues raised in the petition and in the parallel proceeding;
  5. whether the petitioner and the defendant in the parallel proceeding are the same party; and
  6. other circumstances that impact the Board’s exercise of discretion, including the merits.

In Sotera Wireless, the Board noted that the petitioner’s broad stipulation not to pursue in district court any ground that it raised, or reasonably could have raised, in the IPR “weighs strongly in favor of not exercising discretion to deny institution.” The Sotera petition was filed approximately two weeks before the one-year time bar under 35 U.S.C. § 315(b).  At the time of institution, infringement and invalidity contentions had been served in district court, but fact discovery was still ongoing, and trial was set to begin around the time that the Board would issue its final written decision if the IPR was instituted.  The petitioner had filed a stipulation in the district court stating that, if the PTAB instituted the IPR, the petitioner would not pursue in the district court any ground that it raised or reasonably could have raised in the IPR.  The petitioner had also filed a motion to stay, but the district court had not yet ruled on the motion.  Applying a “holistic review” of the Fintiv factors, including (1) that the petition timing was reasonable in view of the number of patents and challenged claims in this and petitioner’s related petitions, (2) the relatively limited investment in the parallel proceeding to date, and (3) the minimal potential overlap between the two proceedings in view of petitioner’s stipulation, the Board declined to deny institution under § 314(a).

In Snap, Inc., the Board noted that a district court stay that would remain in place until a final written decision issued in the IPR “weighed strongly against exercising discretion to deny institution.”  In this case, at the time the petition was filed, preliminary contentions and claim construction positions had been exchanged and initial discovery had begun in the district court, but the court had not yet issued any substantive orders and had stayed the case pending either a denial of institution or a final written decision in the IPR.  Taking a “holistic view” of the Fintiv factors, the Board declined to deny institution under § 314(a), noting (1) the stay in the parallel district court proceeding, (2) the early stages of that parallel proceeding prior to the stay being granted, and (3) the lack of overlap between the invalidity contentions in the district court proceeding and the challenges raised in the petition.

Tags

Patent Trial and Appeal Board (PTAB), 35 U.S.C. § 314(a), 35 U.S.C. § 315(b)

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Life Sciences

Medical Device and Diagnostics

Related Offices

Atlanta, GA

Washington, DC

Contacts

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email
Kevin D. Rodkey
Partner
Atlanta, GA
+1 404 653 6484
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP